PLC Systems trial approved for RenalGuard device

03/20/2008 | FDAnews · Worcester Business Journal (Mass.)

The FDA has cleared PLC Systems' clinical trial for its RenalGuard device, designed to prevent contrast-induced nephropathy, which can cause in-hospital acute renal failure. The product is a fluid-replacement device intended for patients undergoing cardiovascular imaging or radiology procedures using contrast media.

View Full Article in:

FDAnews · Worcester Business Journal (Mass.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC